Litcius/Paper detail

Synthesis and Biological Activity of a VHL-Based PROTAC Specific for p38α

Monica Cubillos‐Rojas, Guillem Loren, Yusuf Zaim Hakim, Xavier Verdaguer, Antoni Riéra, Ángel R. Nebreda

2023Cancers13 citationsDOIOpen Access PDF

Abstract

We report a series of small molecule proteolysis-targeting chimeras (PROTACs) that target the protein kinase p38α for degradation. These PROTACs are based on a ligand of the VHL E3 ubiquitin ligase, which is linked to an ATP competitive inhibitor of p38α. We provide evidence that these compounds can induce the specific degradation of p38α, but not p38β and other related kinases, at nanomolar concentrations in several mammalian cell lines. We also show that the p38α-specific PROTACs are soluble in aqueous solutions and therefore suitable for their administration to mice. Systemic administration of the PROTACs induces p38α degradation only in the liver, probably due to the PROTAC becoming inactivated in that organ, but upon local administration the PROTACs induce p38α degradation in mammary tumors. Our compounds provide an alternative to traditional chemical inhibitors for targeting p38α signaling in cultured cells and in vivo.

Topics & Concepts

ProteolysisUbiquitin ligasep38 mitogen-activated protein kinasesUbiquitinProtein degradationKinaseIn vivoChemistryCell biologyPharmacologyProtein kinase ABiochemistryBiologyBiotechnologyEnzymeGeneProtein Degradation and InhibitorsUbiquitin and proteasome pathwaysPeptidase Inhibition and Analysis
Synthesis and Biological Activity of a VHL-Based PROTAC Specific for p38α | Litcius